Berlex recalls tainted lot of Ultravist CT contrast media
Berlex initiated a nationwide recall July 20 to retrieve a single lot of Ultravist after particulate matter associated with crystallization was found in vials of the intravenous x-ray and CT contrast medium.
Berlex initiated a nationwide recall July 20 to retrieve a single lot of Ultravist after particulate matter associated with crystallization was found in vials of the intravenous x-ray and CT contrast medium.
The recall is limited to lot No. 41500A of Ultravist Injection 370 mgI/mL, 125 mL, (iopromide injection), NDC 50419-346-12. The expiration date is January 2007.
Particulate matter found in the vial poses serious safety problems, including vascular thrombosis, thromboembolism, and injury to the heart, kidney, and brain, the company said in a release.
Berlex voluntarily instigated the recall after two customers complained about vials exhibiting crystallization. An investigation was begun to determine if other lots of Ultravist were affected, the company said
Berlex customers were asked to inspect their inventories for Ultravist from the affected lot. If found, the product should be quarantined immediately to prohibit its use in medical imaging.
Berlex should be contacted at 866/237-5395 to orchestrate the return of contaminated vials. Adverse reactions or quality problems with Ultravist should be reported to the FDA's Medwatch Adverse Event Reporting program or by phone at 800/332-1088.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
